Skip to main content
S&P 5007,516.70-1.00%DOW52,201.91-0.18%NASDAQ24,924.96-1.74%BTC$68,606.00-4.75%ETH$1,932.04-4.29%GOLD$3,875.50-0.25%OIL$88.89+0.17%
Smart Investors Daily
SID Premium
OS

NYSE · OSTX

OS Therapies Incorporated

Healthcare · Biotechnology

$0.75

Down-$0.06 (-7.92%)

Updated Nov 13, 2026, 3:40 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
71.66M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
$0.58 – $2.25
Volume
1.34M
Avg. volume
342.06K

Price performance · OSTX

OSTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

OSTX closed at $0.75 after 21 trading sessions, down 46.80% for the selected period.

Last close
$0.75
Period change
-46.80%
Period low
$0.75
Period high
$1.41
Daily close
View OHLC price history
OSTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$0.8792$0.8792$0.7221$0.75011.34M
Nov 11, 2026$0.8964$0.94$0.86$0.8722327.38K
Nov 10, 2026$0.9576$0.9801$0.8601$0.89404.16K
Nov 9, 2026$0.99$1.08$0.90$0.9201705.9K
Nov 6, 2026$0.98$1.00$0.8402$1.00984.76K
Nov 5, 2026$0.986$1.015$0.5799$0.98013.47M
Nov 4, 2026$1.18$1.21$1.11$1.15503.31K
Nov 3, 2026$1.16$1.22$1.15$1.16439.3K
Nov 2, 2026$1.24$1.30$1.115$1.15932.99K
Oct 30, 2026$1.27$1.2799$1.21$1.24321.73K
Oct 29, 2026$1.25$1.33$1.25$1.30389.19K
Oct 28, 2026$1.24$1.28$1.22$1.25273.89K
Oct 27, 2026$1.22$1.28$1.20$1.23318.15K
Oct 26, 2026$1.27$1.27$1.20$1.21247.66K
Oct 23, 2026$1.27$1.29$1.23$1.25142.13K
Oct 22, 2026$1.27$1.31$1.24$1.25344.36K
Oct 21, 2026$1.27$1.33$1.25$1.27338.05K
Oct 20, 2026$1.30$1.34$1.255$1.26320.66K
Oct 19, 2026$1.33$1.3399$1.23$1.27704.74K
Oct 16, 2026$1.42$1.43$1.30$1.32529.17K
Oct 15, 2026$1.38$1.44$1.375$1.41375.24K

Latest OSTX news

The latest Smart Investors Daily articles mentioning OSTX.

Stock researchCompany · Overview

OSTX research

Overview

Company profile and research snapshot.

Company profile

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.01
Implied upside
—
Analysts
10
OSTX recent ratings
DateFirmRatingTarget
Jul 9, 2026Roth CapitalBuy—
May 19, 2026Lake StreetBuy—
Apr 30, 2026D. Boral CapitalBuy—
Apr 8, 2026D. Boral CapitalBuy—
Mar 27, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

US Based Clinical Stage Oncology Company Begins Critical Step Following Successful September 2026 Scientific Advice MeetingSubmission expected to be accepted in the fourth quarter of 2026Potential early market access decision expected from MHRA in the first quarter of 2027Grasonville, Maryland--(Newsfile Corp. - November 10, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced..

Yahoo · Nov 5, 2026

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

Leading Clinical Stage Oncology Company Now Able to Complete CMMA Submission to U.K's MHRA for Early Commercial Access and Trial AuthorisationGrasonville, Maryland--(Newsfile Corp. - November 5, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has completed the requalification of drug substance used in its Phase 2b trial of OST-HER2 (Herlystic™) in the prevention of.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By